Mylan Inc (NASDAQ:MYL) To Gain From Better Operational Performance Fuelled By Multiple Product Approvals

Boston, MA 10/06/2014 (wallstreetpr) –  Mylan Inc (NASDAQ:MYL) has expressed the confidence that it would be able to gain from better than expected operational performance during the third quarter. The company said that the recent launches and multiple product approvals were supporting its optimism. Boosts Outlook For 3Q Mylan Inc (NASDAQ:MYL) disclosed that the third […]

Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations

Boston, MA 09/16/2014 (wallstreetpr) – In order to sell hepatitis C pill- Sovaldi, in developing countries like South Africa, Vietnam and Honduras, Gilead Sciences, Inc. (NASDAQ:GILD) authorized various drug companies in India. The actual price of hepatitis C pill of the company is $1,000-a-day, which will now be sold at just a dime in the […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) – Nuvigil Patent Infringement Lawsuit Resolved

Boston, MA 06/20/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) continues to file a series of patent infringement lawsuits against various company as it seeks to protect its products from generic competition. It goes without saying that some of these cases result in unnecessary expenses, prompting companies to opt for early settlement as it […]

Mylan Inc (NASDAQ:MYL): Will It Create An Entry Into Pain Management?

Boston, MA 06/05/2014 (wallstreetpr) – Mylan Inc (NASDAQ:MYL) settles the patent litigation with Pfizer relating to the generic version of Celebrex. The Company filed the Abbreviated New Drug Application (ANDA) with the FDA for Celebrex capsules. The product primarily uses for the treatment of arthritis and pain management in adults. Legal Settlement Celebrex’s patent will […]

Mylan Inc. (NASDAQ:MYL) Manages license Agreement With Pfizer Inc. (NYSE:PFE) For Generic Version Of Celebrex

Boston, MA 06/04/2014 (wallstreetpr) – Mylan Inc. (NASDAQ:MYL) made an official announcement about its license agreement to sell the generic version of the painkiller capsules Celecoxib, also referred popularly as Celebrex, with Pfizer Inc. (NYSE:PFE). Abbreviated New Drug Application (ANDA) In answer to the aforementioned application made by Mylan Inc. (NASDAQ:MYL) to the US FDA, […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA): The Time To Sell

Boston, MA 06/03/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is trading near its 52 week high. Seeing the present conditions linked with Copaxone, it is wise to sell the stock or have some cushion by buying the put options. Goldman has warned of a sell off on Teva due to the problems associated […]

Competition Stricken Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) May Look For India Deal Despite Denial

Boston, MA 05/23/2014 (wallstreetpr) – The Israel-based drug company Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has taken several doses of its own medicine in recent times. The company that thrives in developing and marketing generic drugs has in recent times until last week tried to stop competitors from developing a copycat of its bestselling Copaxone […]

Valero Energy Corporation (NYSE:VLO): Dark Days have Overshadowed

Boston, MA 04/09/2014 (wallstreetpr) – Wall Street had seen dramatic changes in the very recent days as most of the investors had escaped from the stock market on Monday with an intensified sell-off. The NYSE also had ended with a dark closing bell on Monday with three major companies finishing-off the day on a worse note. […]

Mylan Inc (NASDAQ:MYL) Makes Acquisition Contact With Swedish Rival Meda, Sues Celgene Corporation (NASDAQ:CELG)

Boston, MA 04/04/2014 (wallstreetpr) – Mylan Inc (NASDAQ:MYL) is said to be considering a bid to acquire Meda, a Swedish competitor, people familiar with the matter said today. The company has reportedly made preliminary discussions about merger, yet details of the talks are yet to be made public. Discussions about merger deal between Mylan and Meda […]